衰老
旁分泌信号
间充质干细胞
肾
生物
纤维化
肾脏疾病
血管生成
肾干细胞
干细胞
细胞生物学
免疫学
癌症研究
生物信息学
医学
病理
内分泌学
祖细胞
受体
遗传学
作者
Seyyedeh Mina Hejazian,Seyyed Sina Hejazian,Shiva Mostafavi,Seyed Mahdi Hosseiniyan,Soheila Montazersaheb,Mohammadreza Ardalan,Sepideh Zununi Vahed,Abolfazl Barzegari
标识
DOI:10.1186/s12964-024-01968-1
摘要
Abstract Cellular senescence is a phenomenon distinguished by the halting of cellular division, typically triggered by DNA injury or numerous stress-inducing factors. Cellular senescence is implicated in various pathological and physiological processes and is a hallmark of aging. The presence of accumulated senescent cells, whether transiently (acute senescence) or persistently (chronic senescence) plays a dual role in various conditions such as natural kidney aging and different kidney disorders. Elevations in senescent cells and senescence-associated secretory phenotype (SASP) levels correlate with decreased kidney function, kidney ailments, and age-related conditions. Strategies involving senotherapeutic agents like senolytics, senomorphics, and senoinflammation have been devised to specifically target senescent cells. Mesenchymal stem cells (MSCs) and their secreted factors may also offer alternative approaches for anti-senescence interventions. The MSC-derived secretome compromises significant therapeutic benefits in kidney diseases by facilitating tissue repair via anti-inflammatory, anti-fibrosis, anti-apoptotic, and pro-angiogenesis effects, thereby improving kidney function and mitigating disease progression. Moreover, by promoting the clearance of senescent cells or modulating their secretory profiles, MSCs could potentially reverse some age-related declines in kidney function. This review article intends to shed light on the present discoveries concerning the role of cellular senescence in kidney aging and diseases. Furthermore, it outlines the role of senotherapeutics utilized to alleviate kidney damage and aging. It also highlights the possible impact of MSCs secretome on mitigating kidney injury and prolonging lifespan across various models of kidney diseases as a novel senotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI